Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 1438-1439, 2006; 10.1373/clinchem.2006.069427
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Decock, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Decock, J.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2006;52:1438-1439.)
© 2006 American Association for Clinical Chemistry, Inc.

Letters to the Editor

How Accurate Is the Antiprimer Quenching-Based Real-Time PCR for Detection of Her2/neu in Clinical Cancer Samples?

Julie Decock

Laboratory for, Experimental Oncology, Department of, General Medical Oncology, University Hospital Gasthuisberg, Onderwijs & Navorsing 1, Room 815, Herestraat 49, 3000 Leuven, Belgium, Fax 32-1634-6901, E-mail julie.decock@med.kuleuven.be

The first 20% of the full text of this article appears below.


To the Editor:

I read with great interest the recent article by Li et al. (1), in which they presented a novel, cost-effective quantitative PCR technology for the analysis of clinical cancer samples. They developed an antiprimer quenching-based real-time PCR (aQRT-PCR) that uses fluorescently labeled PCR primers in combination with a universal quenching antiprimer, reducing the cost of labeling. In agreement with their in-house fluorescence in situ hybridization (FISH) and immunohistochemistry results, their multiplex aQRT-PCR approach detected chromosomal Her2/neu amplification in microdissected breast cancer samples; in formalin-fixed, paraffin-embedded specimens; and in plasma circulating DNA. Hence, Li et al. (1) concluded . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.